Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Davidson, BA; Squatrito, R; Duska, LR; Havrilesky, LJ; Schwager, N; McCollum, M; Arapovic, S; Secord, AA

Published Date

  • May 20, 2016

Published In

Volume / Issue

  • 34 / 15_suppl

Start / End Page

  • TPS5601 - TPS5601

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2016.34.15_suppl.tps5601